Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

Related Citations for PubMed (Select 24874245)

1.

Targeting human equilibrative nucleoside analog transporter (hENT1) expression through modified low glycemic index diet in pancreatic cancer.

Pazienza V, Del Nobile Matteo A.

Biomed Pharmacother. 2014 Jun;68(5):663-4. doi: 10.1016/j.biopha.2014.04.009. Epub 2014 May 2.

PMID:
24874245
2.

Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody.

Ormanns S, Heinemann V, Raponi M, Isaacson J, Laubender RP, Haas M, Kruger S, Kleespies A, Mann E, Bartosiewicz M, Kirchner T, Boeck S.

Eur J Cancer. 2014 Jul;50(11):1891-9. doi: 10.1016/j.ejca.2014.04.023. Epub 2014 May 20.

PMID:
24857044
3.

Human equilibrative nucleoside transporter 1 (hENT1) predicts the Asian patient response to gemcitabine-based chemotherapy in pancreatic cancer.

Xiao JC, Zhang TP, Zhao YP.

Hepatogastroenterology. 2013 Mar-Apr;60(122):258-62. doi: 10.5754/hge12687.

PMID:
23574652
4.

The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.

Spratlin J, Sangha R, Glubrecht D, Dabbagh L, Young JD, Dumontet C, Cass C, Lai R, Mackey JR.

Clin Cancer Res. 2004 Oct 15;10(20):6956-61.

5.

Human equilibrative nucleoside transporter 1 predicts survival in patients with pancreatic cancer treated with gemcitabine: a meta-analysis.

Zhu Y, Qi M, Lao L, Wang W, Hua L, Bai G.

Genet Test Mol Biomarkers. 2014 May;18(5):306-12. doi: 10.1089/gtmb.2013.0419. Epub 2014 Mar 13.

PMID:
24625353
6.

Immunohistochemical analysis of human equilibrative nucleoside transporter-1 (hENT1) predicts survival in resected pancreatic cancer patients treated with adjuvant gemcitabine monotherapy.

Morinaga S, Nakamura Y, Watanabe T, Mikayama H, Tamagawa H, Yamamoto N, Shiozawa M, Akaike M, Ohkawa S, Kameda Y, Miyagi Y.

Ann Surg Oncol. 2012 Jul;19 Suppl 3:S558-64. doi: 10.1245/s10434-011-2054-z. Epub 2011 Sep 13.

PMID:
21913012
7.

Human equilibrative nucleoside transporter 1 (hENT1): do we really have a new predictive biomarker of chemotherapy outcome in pancreatic cancer patients?

Mohelnikova-Duchonova B, Melichar B.

Pancreatology. 2013 Nov-Dec;13(6):558-63. doi: 10.1016/j.pan.2013.09.005. Epub 2013 Oct 10.

PMID:
24280569
8.

Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1 (hENT1) enhances gemcitabine response in human pancreatic cancer.

Pérez-Torras S, García-Manteiga J, Mercadé E, Casado FJ, Carbó N, Pastor-Anglada M, Mazo A.

Biochem Pharmacol. 2008 Aug 1;76(3):322-9. doi: 10.1016/j.bcp.2008.05.011. Epub 2008 May 20.

PMID:
18589402
9.

Human equilibrative nucleoside transporter 1 level does not predict prognosis in pancreatic cancer patients treated with neoadjuvant chemoradiation including gemcitabine.

Kawada N, Uehara H, Katayama K, Nakamura S, Takahashi H, Ohigashi H, Ishikawa O, Nagata S, Tomita Y.

J Hepatobiliary Pancreat Sci. 2012 Nov;19(6):717-22. doi: 10.1007/s00534-012-0514-x. Erratum in: J Hepatobiliary Pancreat Sci. 2012 Nov;19(6):723.

PMID:
22426593
10.

Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.

Farrell JJ, Elsaleh H, Garcia M, Lai R, Ammar A, Regine WF, Abrams R, Benson AB, Macdonald J, Cass CE, Dicker AP, Mackey JR.

Gastroenterology. 2009 Jan;136(1):187-95. doi: 10.1053/j.gastro.2008.09.067. Epub 2008 Oct 7.

PMID:
18992248
11.

Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma.

Maréchal R, Mackey JR, Lai R, Demetter P, Peeters M, Polus M, Cass CE, Young J, Salmon I, Devière J, Van Laethem JL.

Clin Cancer Res. 2009 Apr 15;15(8):2913-9. doi: 10.1158/1078-0432.CCR-08-2080. Epub 2009 Mar 24.

12.

Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3-T4 pancreatic cancer patients treated with preoperative gemcitabine-based chemoradiotherapy.

Murata Y, Hamada T, Kishiwada M, Ohsawa I, Mizuno S, Usui M, Sakurai H, Tabata M, Ii N, Inoue H, Shiraishi T, Isaji S.

J Hepatobiliary Pancreat Sci. 2012 Jul;19(4):413-25. doi: 10.1007/s00534-011-0440-3.

PMID:
21898089
13.

Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer.

Santini D, Vincenzi B, Fratto ME, Perrone G, Lai R, Catalano V, Cass C, Ruffini PA, Spoto C, Muretto P, Rizzo S, Muda AO, Mackey JR, Russo A, Tonini G, Graziano F.

J Cell Physiol. 2010 May;223(2):384-8. doi: 10.1002/jcp.22045.

PMID:
20082300
15.

Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'-difluorodeoxycytidine- induced cytotoxicity.

García-Manteiga J, Molina-Arcas M, Casado FJ, Mazo A, Pastor-Anglada M.

Clin Cancer Res. 2003 Oct 15;9(13):5000-8.

16.

The role of human equilibrative nucleoside transporter 1 on the cellular transport of the DNA methyltransferase inhibitors 5-azacytidine and CP-4200 in human leukemia cells.

Hummel-Eisenbeiss J, Hascher A, Hals PA, Sandvold ML, Müller-Tidow C, Lyko F, Rius M.

Mol Pharmacol. 2013 Sep;84(3):438-50. doi: 10.1124/mol.113.086801. Epub 2013 Jun 28.

17.

Human Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions.

Spratlin JL, Mackey JR.

Cancers (Basel). 2010 Dec 2;2(4):2044-54. doi: 10.3390/cancers2042044.

18.
19.

Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma.

Borbath I, Verbrugghe L, Lai R, Gigot JF, Humblet Y, Piessevaux H, Sempoux C.

Eur J Cancer. 2012 May;48(7):990-6. doi: 10.1016/j.ejca.2011.11.006. Epub 2011 Dec 1.

PMID:
22137164
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk